Literature DB >> 7387138

In vitro and in vivo antibacterial activity of KW1070, a new aminoglycoside antibiotic.

Y Ohashi, H Kawabe, K Sato, N Nakamura, S Kurashige, S Mitsuhashi.   

Abstract

KW1070, a new aminoglycoside antibiotic with the novel aminocyclitol, fortamine, has a broad spectrum of activity in vitro and in vivo against gram-positive and gram-negative bacteria. The minimum inhibitory concentrations of KW1070 are similar to those of kanamycin against aminoglycoside-susceptible strains, slightly less than those of gentamicin or 3',4'-dideoxykanamycin B. Minimal bactericidal concentrations were found to be near minimal inhibitory concentrations. KW1070 was active in vitro against many aminoglycoside-resistant bacterial strains that possess aminoglycoside-inactivating enzymes, particularly AAC(6'), AAC(2'), AAD(2''), and APH(3'). The activities of KW1070 in mice infected with Staphylococcus aureus, Escherichia coli, Proteus sp., and Serratia marcescens compared favorably with the activities of amikacin and kanamycin; KW1070 was also singificantly active in mice infected with resistant strains bearing the aminoglycoside-inactivating enzymes listed above.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7387138      PMCID: PMC283748          DOI: 10.1128/AAC.17.2.138

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Fortimicins A and B, new aminoglycoside antibiotics. I. Producing organism, fermentation and biological properties of fortimicins.

Authors:  T Nara; M Yamamoto; I Kawamoto; K Takayama; R Okachi; S Takasawa; T Sato; S Sato
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

2.  Fortimicins A and B, new aminoglycoside antibiotics. III. Structural identification.

Authors:  R S Egan; R S Stanaszek; M Cirovic; S L Mueller; J Tadanier; J R Martin; P Collum; A W Goldstein; R L De Vault; A C Sinclair; E E Fager; L A Mitscher
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

3.  Enzymatic acetylation of fortimicin A and seldomycin factor 5 by aminoglycoside 3-acetyltransferase I: [AAC(3)-I] of E. coli KY8348.

Authors:  S Sato; T Iida; R Okachi; K Shirahata; T Nara
Journal:  J Antibiot (Tokyo)       Date:  1977-11       Impact factor: 2.649

4.  Fortimicins A and B, new aminoglycoside antibiotics. IV. In vitro study of fortimicin A compared with other aminoglycosides.

Authors:  R L Girolami; J M Stamm
Journal:  J Antibiot (Tokyo)       Date:  1977-07       Impact factor: 2.649

5.  R factor-mediated aminoglycoside antibiotic resistance in Pseudomonas aeruginosa: a new aminoglycoside 6'-N-acetyltransferase.

Authors:  H Kawabe; S Kondo; H Umezawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

  5 in total
  4 in total

1.  Comparative antimicrobial activity of O-demethylfortimicin A, a derivative of fortimicin A.

Authors:  R L Girolami; J M Stamm
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

2.  Synergistic activities of fortimicin A and beta-lactam antibiotics against Pseudomonas aeruginosa.

Authors:  K Yamashita; H Kawabe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of K-4619, a new semisynthetic aminoglycoside.

Authors:  Y Saino; Y Hattori; T Koshi; F Kobayashi; T Oda; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of dactimicin, a novel pseudodisaccharide aminoglycoside, compared with those of other aminoglycoside antibiotics.

Authors:  Y Matsuhashi; T Yoshida; T Hara; Y Kazuno; S Inouye
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.